<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">HET</journal-id>
<journal-id journal-id-type="hwp">sphet</journal-id>
<journal-id journal-id-type="nlm-ta">Hum Exp Toxicol</journal-id>
<journal-title>Human &amp; Experimental Toxicology</journal-title>
<issn pub-type="ppub">0960-3271</issn>
<issn pub-type="epub">1477-0903</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0960327112454891</article-id>
<article-id pub-id-type="publisher-id">10.1177_0960327112454891</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Effects of fenofibrate, a PPAR-α ligand, on the haemodynamics of glycerol-induced renal failure in rats</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Adedapo</surname>
<given-names>AA</given-names>
</name>
<xref ref-type="corresp" rid="corresp1-0960327112454891"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Oyekan</surname>
<given-names>AO</given-names>
</name>
</contrib>
<aff id="aff1-0960327112454891">Center for Cardiovascular Diseases, College of Pharmacy and Health Sciences, Texas Southern University, Houston TX, USA</aff>
</contrib-group>
<author-notes>
<corresp id="corresp1-0960327112454891">Adeolu A Adedapo, Faculty of Veterinary Medicine, University of Ibadan, Ibadan 200005, Nigeria. Email: <email>aa.adedapo@ui.edu.ng</email>
</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>3</month>
<year>2013</year>
</pub-date>
<volume>32</volume>
<issue>3</issue>
<fpage>323</fpage>
<lpage>331</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The modulating effect of peroxisome proliferator-activated receptor α ligand on haemodynamic effects of phenylepherine (PE), angiotensin II (AII), endothelin 1 (ET1), acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were evaluated in glycerol-induced acute kidney injury in rats. The effect of PE on fenofibrate-treated animals was a dose-dependent increase in mean arterial blood pressure (MAP). For AII and ET1, MAP was also increased for the fenofibrate group but not in a dose-dependent fashion. On the medullary blood flow (MBF), while the lower doses of PE and AII increased the perfusion unit on the fenofibrate-treated group, the higher doses decreased the perfusion unit. The ET1 increased the perfusion unit on this group but not in dose-dependent fashion. The effects of PE and AII on the cortical blood flow (CBF) of fenofibrate-treated group is similar to that of MBF for the same group but not for ET1. The effect of Ach, SNP and ISO in all the groups was the decrease in MAP. ISO caused dose-dependent increase in MBF of fenofibrate-treated group. The effect of Ach, SNP and ISO on the CBF perfusion unit was that of the increase for the fenofibrate-treated group. The study showed that fenofibrate did not attenuate increased blood pressure induced by PE, AII and ET1 but caused enhanced vasodilation by Ach, SNP and ISO.</p>
</abstract>
<kwd-group>
<kwd>Fenofibrate</kwd>
<kwd>acute kidney injury</kwd>
<kwd>vasoconstrictors</kwd>
<kwd>vasodilators</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-0960327112454891">
<title>Introduction</title>
<p>Glycerol-induced acute renal failure (ARF) is characterized by myoglobinuria and tubular necrosis.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112454891">1</xref>
</sup> In addition, ARF is characterized by increased vasoconstriction.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454891">2</xref>
</sup> ARF now known as acute kidney injury (AKI) represents a significant and devastating problem in clinical medicine.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112454891">3</xref>,<xref ref-type="bibr" rid="bibr4-0960327112454891">4</xref>
</sup> The incidence of AKI varies from 5% of hospitalized patients to 30–50% of patients in intensive care units, and there is now substantial evidence that the incidence is rising at an alarming rate.<sup>
<xref ref-type="bibr" rid="bibr5-0960327112454891">5</xref>
</sup> Despite significant improvements in therapeutics, the mortality and morbidity associated with AKI remain high. Outstanding advances in basic research have illuminated the pathogenesis of AKI and have paved the way for successful therapeutic approaches in animal models.<sup>
<xref ref-type="bibr" rid="bibr3-0960327112454891">3</xref>
</sup> However, translational research efforts in humans have yielded disappointing results.<sup>
<xref ref-type="bibr" rid="bibr6-0960327112454891">6</xref>
</sup>
</p>
<p>Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear hormone receptor superfamily of ligand-activated transcription factors that are related to retinoid, steroid and thyroid hormone receptors.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112454891">7</xref>
</sup> The PPAR subfamily consists of three members: PPAR-α, PPAR-β(δ) and PPAR-γ.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454891">2</xref>
</sup> Most tissues in humans and rodents have all three receptor subtypes, although there is considerable variability in the relative expression.<sup>
<xref ref-type="bibr" rid="bibr7-0960327112454891">7</xref>
</sup>
</p>
<p>PPAR-γ is expressed in adipose tissue,<sup>
<xref ref-type="bibr" rid="bibr8-0960327112454891">8</xref>
</sup> endothelial cells<sup>
<xref ref-type="bibr" rid="bibr9-0960327112454891">9</xref>
</sup> and vascular smooth muscle cells (VSMCs).<sup>
<xref ref-type="bibr" rid="bibr10-0960327112454891">10</xref>
</sup> Activation of PPAR-γ in VSMCs inhibits proliferation and migration, the release of matrix-degrading enzyme, matrix-metalloproteinase-9 expression and oxidative stress, suggesting its role in vascular function.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112454891">1</xref>
</sup> The activation of PPAR-γ suppresses the transcription of angiotensin type-1 receptor,<sup>
<xref ref-type="bibr" rid="bibr11-0960327112454891">11</xref>
</sup> decreases blood pressure,<sup>
<xref ref-type="bibr" rid="bibr12-0960327112454891">12</xref>
</sup> ameliorated microalbuminuria<sup>
<xref ref-type="bibr" rid="bibr13-0960327112454891">13</xref>
</sup> and decreases insulin resistance.<sup>
<xref ref-type="bibr" rid="bibr14-0960327112454891">14</xref>
</sup> These observations indicate that a role exists for PPAR-γ in the regulation of renal and systemic haemodynamics and that PPAR-γ ligands can protect against renal injury.</p>
<p>The PPAR-α is a fatty acid-activated nuclear receptor that plays a key role in the transcriptional regulation of genes involved in cellular lipid and energy metabolism. PPAR-α is expressed in tissues with very active fatty acid metabolism such as the heart, kidney, liver and the endothelium<sup>
<xref ref-type="bibr" rid="bibr15-0960327112454891">15</xref>
</sup> and in VSMCs,<sup>
<xref ref-type="bibr" rid="bibr16-0960327112454891">16</xref>
</sup> suggesting that PPARα may exert direct effects on the vascular wall.<sup>
<xref ref-type="bibr" rid="bibr17-0960327112454891">17</xref>
</sup> Fatty acids and their derivatives have been identified as natural ligands for PPAR-α, and PPAR-α is the primary target of numerous classes of synthetic ligands, including lipid-lowering fibrates and gemfibrozil.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112454891">18</xref>
</sup>
</p>
<p>Although the effect of fibrates is generally attributed mainly to their hypolipidemic and high-density lipoprotein-raising actions, they possess other actions on the vasculature such as anti-inflammatory, antiproliferative and renoprotective effects that may contribute to their beneficial effects.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112454891">18</xref>
<xref ref-type="bibr" rid="bibr19-0960327112454891"/>
<xref ref-type="bibr" rid="bibr20-0960327112454891"/>–<xref ref-type="bibr" rid="bibr21-0960327112454891">21</xref>
</sup> PPAR-α activation therefore reduced arterial low-density lipoprotein accumulation and endothelial layer permeability in the arterial wall in angiotensin II (AII)-induced vascular inflammation and atherosclerosis in mice.<sup>
<xref ref-type="bibr" rid="bibr22-0960327112454891">22</xref>
</sup>
</p>
<p>PPAR-α together with PPAR-δ and PPAR-γ forms a subgroup within the nuclear receptor superfamily.<sup>
<xref ref-type="bibr" rid="bibr14-0960327112454891">14</xref>
</sup> In contrast to PPAR-α, which is involved in the control of cellular lipid utilization, PPAR-γ has been shown to be a necessary component of the adipocyte differentiation program.<sup>
<xref ref-type="bibr" rid="bibr14-0960327112454891">14</xref>
</sup>
</p>
<p>The biological function of PPAR-δ is unknown. A diverse group of compounds can act as activating ligands for PPAR-α including several prostaglandin derivatives, eicosanoids and long-chain unsaturated fatty acids.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112454891">1</xref>
</sup> To date, the majority of PPAR-α target genes identified are involved in cellular fatty acid oxidation.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454891">2</xref>
</sup>
</p>
<p>Although the modulating effects of PPAR-α on haemodynamic effects elicited by AII under normal conditions have been studied; efforts were therefore made in this study to evaluate the haemodynamic effects of PPAR-α ligand, fenofibrate in glycerol-induced renal failure in rats. The study thus assessed the effects of a ligand of these nuclear hormone receptors on three vasoconstrictors and three vasodilators and hence its ability to ameliorate high blood pressure in ARF setting.</p>
</sec>
<sec id="section2-0960327112454891" sec-type="materials|methods">
<title>Materials and methods</title>
<p>Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich (St Louis, Missouri, USA). Fenofibrate was prepared in mineral oil, while 50% glycerol was prepared in double distilled water. The vasoconstrictors phenylepherine (PE), AII and endothelin 1 (ET1) and the vasodilators acetylcholine (Ach), sodium nitroprusside (SNP) and isoproterenol (ISO) were kept on ice during the experiments.</p>
<sec id="section3-0960327112454891">
<title>Animal studies</title>
<p>The studies were carried out using adult male albino rats (age 9–12 months old; weight 350 ± 5 g) obtained from Harlan Sprague-Dawley (Houston, Texas, USA). The animals were maintained on a standard rat feed (Purina Chowo; Harlan Sprague-Dawley) and allowed ad libitum access to water and food until the day when the haemodynamic experiments will be conducted. Animals were randomly divided into the following groups:<list list-type="order">
<list-item>
<p>Control groups comprised rats treated with mineral oil (vehicle, 1 ml/kg) (<italic>n</italic> = 7) and double distilled water (<italic>n</italic> = 7).</p>
</list-item>
<list-item>
<p>On the other hand, the ARF groups comprised (a) ARF rats treated with PPAR-α ligand (fenofibrate; <italic>n</italic> = 7) and (b) ARF-untreated rats or glycerol (<italic>n</italic> = 9).</p>
</list-item>
</list>
</p>
</sec>
<sec id="section4-0960327112454891">
<title>Induction of ARF in rats</title>
<p>ARF was induced using the standard method involving administration of 50% glycerol (v/v, 4 ml/kg, intramuscularly). The 50% glycerol was obtained by dissolving glycerol in double distilled water. After 7 days of study period in which the different groups received their specific treatment orally, the required amount of glycerol was administered as a deep intramuscular injection equally distributed to both hind legs. Rats were deprived of food and water for 24 h after glycerol administration.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112454891">1</xref>
</sup> After injecting glycerol, rats were placed in individual metabolic cages for collecting 24 h urine sample used for biochemical analysis.</p>
</sec>
<sec id="section5-0960327112454891">
<title>Biochemical analysis</title>
<p>Renal function of the rats was assessed to determine the extent of renal failure by measuring urinary excretion of protein. Urinary protein was measured spectrophotometrically using a kit from Sigma.</p>
</sec>
<sec id="section6-0960327112454891">
<title>Physiological (haemodynamic) measurements</title>
<p>In every group, rats were anaesthetized with intraperitoneal injection of inactin (100 mg/kg; Research Biochemicals International, Natick, Massachusetts, USA) and placed on a heated platform to maintain body temperature at 37°C. A tracheostomy (PE 250; Becton Dickinson and Co., Sparks, Maryland, USA) was performed for spontaneous ventilation and a cannula (PE 250; Becton Dickinson and Co., Sparks, Maryland, USA) was placed in the right carotid artery to monitor blood pressure. A tail vein was also cannulated with a 23-G butterfly needle (Abbott Hospitals Inc., Illinois, USA) for drug administration. The left lateral side of each animal was incised so as to expose the left kidney since this was closer to the surface than its right counterpart. The mean arterial blood pressure (MAP) was measured with a pressure transducer (Statham model P231D; Statham, Oxnard, California, USA) connected to a signal manifold (Transbridge, model TBM-4; World Precision Instruments, Sarasota, Florida, USA) and recorded on a data acquisition system (Model D1720; DataQ Instruments, Akron, Ohio, USA). The cortical blood flow (CBF) was measured by a laser Doppler flow meter (Periflux System 5000, version 1.20; Perimed, Stockholm, Sweden) via a surface probe.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112454891">18</xref>
</sup> Medullary blood flow (MBF) was also measured by a laser Doppler flow meter via fibre optic that was inserted into the kidney.</p>
<p>Following instrumentation as detailed above, anaesthetized rats were allowed to equilibrate for 45 min, after which the effects of vasoconstrictors (PE, AII and ET1) and vasodilators (Ach, SNP and ISO) were tested for the MAP, MBF and CBF.</p>
</sec>
<sec id="section7-0960327112454891">
<title>Data analysis</title>
<p>Haemodynamic responses were recorded as changes (Δ) relative to baseline (preinjection values). Data were expressed as the mean ± SEM and were subjected to analysis of variance. Significant means were separated using Duncan Multiple Range Test of SAS (1999). Bars with different superscripts a, b and ab are significantly different at <italic>p</italic> &lt; 0.05, while bars with similar superscript are not significantly different at <italic>p</italic> &lt; 0.05. All the groups were compared with one another.</p>
</sec>
</sec>
<sec id="section8-0960327112454891">
<title>Results</title>
<sec id="section9-0960327112454891">
<title>Biochemical analysis</title>
<p>Results of the urinary protein showed that ARF was established for the mineral oil and ARF-untreated groups, because on day 1, the urinary protein was 19 and 16 mg/ml, respectively, whereas after glycerol administration, the urinary protein concentration was 59 and 62 mg/ml, respectively. The ARF-untreated group also followed this pattern but not so for the fenofibrate group (<xref ref-type="table" rid="table1-0960327112454891">Table 1</xref>).</p>
<table-wrap id="table1-0960327112454891" position="float">
<label>Table 1.</label>
<caption>
<p>Urinary protein concentration of different groups in this study (X ± SEM).</p>
</caption>
<graphic alternate-form-of="table1-0960327112454891" xlink:href="10.1177_0960327112454891-table1.tif"/>
<table>
<thead>
<tr>
<th rowspan="2">Group</th>
<th colspan="3">Urinary protein concentration (mg/ml)</th>
</tr>
<tr>
<th>Day 1</th>
<th>Day 7</th>
<th>After glycerol administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mineral oil</td>
<td>19 ± 2.1</td>
<td>39 ± 1.5</td>
<td>59 ± 2.2</td>
</tr>
<tr>
<td>Fenofibrate</td>
<td>18 ± 1.2</td>
<td>37 ± 1.6</td>
<td>61 ± 0.9</td>
</tr>
<tr>
<td>Double distilled water</td>
<td>16 ± 0.5</td>
<td>32 ± 1.8</td>
<td>60 ± 2.1</td>
</tr>
<tr>
<td>ARF-untreated</td>
<td>17 ± 2.3</td>
<td>34 ± 1.5</td>
<td>62 ± 2.6</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0960327112454891">
<p>ARF: acute renal failure.</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section10-0960327112454891">
<title>Effects of drugs on MAP</title>
<p>PE caused a dose-dependent increase in the MAP of fenofibrate group. This effect is similar in other groups. The effects of AII and ET1 were similar to that of PE, although less in magnitude. The effect of Ach on MAP was that of decrease but this was more pronounced in the mineral oil group than the others. The 10 ng/kg dose of SNP caused a more lowering of the blood pressure in the fenofibrate group than the others. This is similar to the 30-µg/kg dose of ISO that caused a more lowering of the MAP in the fenofibrate group than others in this category (<xref ref-type="fig" rid="fig1-0960327112454891">Figures 1</xref> to <xref ref-type="fig" rid="fig2-0960327112454891"/>
<xref ref-type="fig" rid="fig3-0960327112454891"/>
<xref ref-type="fig" rid="fig4-0960327112454891"/>
<xref ref-type="fig" rid="fig5-0960327112454891"/>
<xref ref-type="fig" rid="fig6-0960327112454891">6</xref>).</p>
<fig id="fig1-0960327112454891" position="float">
<label>Figure 1.</label>
<caption>
<p>Effects of PE on MAP of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. PE: phenylepherine; MAP: mean arterial blood pressure.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig1.tif"/>
</fig>
<fig id="fig2-0960327112454891" position="float">
<label>Figure 2.</label>
<caption>
<p>Effects of AII (ng/kg) on MAP of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. AII: angiotensin II; MAP: mean arterial blood pressure.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig2.tif"/>
</fig>
<fig id="fig3-0960327112454891" position="float">
<label>Figure 3.</label>
<caption>
<p>Effects of ET1 (ng/kg) on MAP of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. ET1: endothelin 1; MAP: mean arterial blood pressure.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig3.tif"/>
</fig>
<fig id="fig4-0960327112454891" position="float">
<label>Figure 4.</label>
<caption>
<p>Effects of Ach (ng/kg) on the MAP of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. Ach: acetylcholine; MAP: mean arterial blood pressure.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig4.tif"/>
</fig>
<fig id="fig5-0960327112454891" position="float">
<label>Figure 5.</label>
<caption>
<p>Effects of SNP (ng/kg) on the MAP of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. SNP: sodium nitroprusside; MAP: mean arterial blood pressure.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig5.tif"/>
</fig>
<fig id="fig6-0960327112454891" position="float">
<label>Figure 6.</label>
<caption>
<p>Effects of ISO (µg/kg) on the MAP of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. MAP: mean arterial blood pressure; ISO: isoproterenol.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig6.tif"/>
</fig>
</sec>
<sec id="section11-0960327112454891">
<title>Effects of drug on MBF</title>
<p>The effects of PE on the MBF of rats in the different groups did not follow a definite pattern. The 10-µg/kg dose of PE experienced the highest increase in perfusion unit in the glycerol group. Meanwhile, the 30-µg/kg dose also caused the least perfusion unit in the fenofibrate group. The effect of AII followed the pattern of PE to some extent, but for ET1, the 30-ng/kg dose caused the highest perfusion unit in the mineral oil group and the 100-ng/kg dose caused the least perfusion unit in the glycerol group. While the Ach and SNP caused more pronounced perfusion unit in the distilled water group, the effect of ISO on the MBF is that of dose-dependent increase in the fenofibrate group. It must be stated that 30 ng/kg dose of Ach (Figure 10) caused significant difference in perfusion unit in fenofibrate-treated animals relative to other groups and doses except that of the 30-ng/kg dose of the distilled water group (<xref ref-type="fig" rid="fig7-0960327112454891">Figures 7</xref> to <xref ref-type="fig" rid="fig8-0960327112454891"/>
<xref ref-type="fig" rid="fig9-0960327112454891"/>
<xref ref-type="fig" rid="fig10-0960327112454891"/>
<xref ref-type="fig" rid="fig11-0960327112454891"/>
<xref ref-type="fig" rid="fig12-0960327112454891">12</xref>).</p>
<fig id="fig7-0960327112454891" position="float">
<label>Figure 7.</label>
<caption>
<p>Effects of PE (µg/kg) on the MBF of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. PE: phenylepherine; MBF: medullary blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig7.tif"/>
</fig>
<fig id="fig8-0960327112454891" position="float">
<label>Figure 8.</label>
<caption>
<p>Effects of AII (ng/kg) on the MBF of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. AII: angiotensin II; MBF: medullary blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig8.tif"/>
</fig>
<fig id="fig9-0960327112454891" position="float">
<label>Figure 9.</label>
<caption>
<p>Effects of ET1 (ng/kg) on the MBF of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. ET1: endothelin 1; MBF: medullary blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig9.tif"/>
</fig>
<fig id="fig10-0960327112454891" position="float">
<label>Figure 10.</label>
<caption>
<p>Effects of Ach (ng/kg) on the MBF of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. Ach: acetylcholine; MBF: medullary blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig10.tif"/>
</fig>
<fig id="fig11-0960327112454891" position="float">
<label>Figure 11.</label>
<caption>
<p>Effects of SNP (ng/kg) on the MBF of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. SNP: sodium nitroprusside; MBF: medullary blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig11.tif"/>
</fig>
<fig id="fig12-0960327112454891" position="float">
<label>Figure 12.</label>
<caption>
<p>Effects of ISO (µg/kg) on the MBF of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. MBF: medullary blood flow; ISO: isoproterenol.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig12.tif"/>
</fig>
</sec>
<sec id="section12-0960327112454891">
<title>Effect of drugs on CBF</title>
<p>While the 3-µg/kg dose of PE caused the highest level of perfusion units of rats in the fenofibrate group, the 30-µg/kg dose also caused the least perfusion unit (−40 mmHg) in the same group. The effect of AII on the CBF is more pronounced on the mineral oils and the fenofibrate groups, whereas it caused least perfusion units in the 30 and 100 ng/kg doses. The ET1 caused increased perfusion unit in the fenofibrate group in almost a dose-dependent fashion. The effect of Ach on CBF is that of increase in a dose-dependent manner in the fenofibrate group. In the case of SNP, while the 10-ng/kg dose caused highest perfusion unit in all the groups, it was the 100-ng/kg dose that caused the least perfusion unit in the fenofibrate and distilled water groups. The effect of ISO is that of dose-dependent decrease in the perfusion unit in the fenofibrate group. In other words, the 1-µg/kg dose caused more perfusion unit than the others (<xref ref-type="fig" rid="fig13-0960327112454891">Figures 13</xref> to <xref ref-type="fig" rid="fig14-0960327112454891"/>
<xref ref-type="fig" rid="fig15-0960327112454891"/>
<xref ref-type="fig" rid="fig16-0960327112454891"/>
<xref ref-type="fig" rid="fig17-0960327112454891"/>
<xref ref-type="fig" rid="fig18-0960327112454891">18</xref>).</p>
<fig id="fig13-0960327112454891" position="float">
<label>Figure 13.</label>
<caption>
<p>Effects of PE (µg/kg) on the CBF of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. PE: phenylepherine; CBF: cortical blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig13.tif"/>
</fig>
<fig id="fig14-0960327112454891" position="float">
<label>Figure 14.</label>
<caption>
<p>Effects of AII (ng/kg) on the CBF of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. AII: angiotensin II; CBF: cortical blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig14.tif"/>
</fig>
<fig id="fig15-0960327112454891" position="float">
<label>Figure 15.</label>
<caption>
<p>Effects of ET1 (ng/kg) on the CBF of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. ET1: endothelin 1; CBF: cortical blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig15.tif"/>
</fig>
<fig id="fig16-0960327112454891" position="float">
<label>Figure 16.</label>
<caption>
<p>Effects of Ach (ng/kg) on the CBF of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. Ach: acetylcholine; CBF: cortical blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig16.tif"/>
</fig>
<fig id="fig17-0960327112454891" position="float">
<label>Figure 17.</label>
<caption>
<p>Effects of SNP (ng/kg) on the CBF of rats. Note that bar with similar superscripts are not significantly different at <italic>p</italic> &lt; 0.05. SNP: sodium nitroprusside; CBF: cortical blood flow.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig17.tif"/>
</fig>
<fig id="fig18-0960327112454891" position="float">
<label>Figure 18.</label>
<caption>
<p>Effects of ISO (µg/kg) on the CBF of rats. Note that bar with different superscripts are significantly different at <italic>p</italic> &lt; 0.05. CBF: cortical blood flow; ISO: isoproterenol.</p>
</caption>
<graphic xlink:href="10.1177_0960327112454891-fig18.tif"/>
</fig>
</sec>
</sec>
<sec id="section13-0960327112454891">
<title>Discussion</title>
<p>In this study, we have demonstrated that the administration of 50% glycerol could actually lead to the development of AKI as evidenced by high urinary protein. Glycerol-induced ARF is characterized by myoglobinuria and tubular necrosis.<sup>
<xref ref-type="bibr" rid="bibr1-0960327112454891">1</xref>
</sup> Glycerol-induced ARF is a phenomenon widely recognized experimental model of myoglobinuric nephropathy, and the renal vasoconstriction seen in the initial phase of the injury is considered as an important pathogenic event.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454891">2</xref>
</sup> Increased renal production of AII and thromboxane A<sub>2</sub> (TxA<sub>2</sub>) have been reported suggesting a role for AII and TxA<sub>2</sub> as mediators of the vasoconstriction and the decrease in renal function seen after glycerol administration.<sup>
<xref ref-type="bibr" rid="bibr2-0960327112454891">2</xref>,<xref ref-type="bibr" rid="bibr23-0960327112454891">23</xref>
</sup> However, it is interesting to note that 24 h after glycerol administration to the fenofibrate group, the urinary protein actually experienced a decrease in its level when compared with day 7 of drug administration. This observation would give impression that ARF was not developed. However, one would like to state that fenofibrate like other PPAR activators have anti-inflammatory activities.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112454891">18</xref>
</sup> Studies showed that PPAR activation confers cardioprotective effects that seem to involve modulation of the nitric oxide (NO)/NO synthase system.<sup>
<xref ref-type="bibr" rid="bibr24-0960327112454891">24</xref>
<xref ref-type="bibr" rid="bibr25-0960327112454891"/>–<xref ref-type="bibr" rid="bibr26-0960327112454891">26</xref>
</sup> In this regard, clinical observations showing that PPAR-α activators lower the progression of atherosclerotic lesions<sup>
<xref ref-type="bibr" rid="bibr25-0960327112454891">25</xref>,<xref ref-type="bibr" rid="bibr26-0960327112454891">26</xref>
</sup> was ascribed to increased NO, which is known to be antiatherogenic and anti-inflammatory.<sup>
<xref ref-type="bibr" rid="bibr27-0960327112454891">27</xref>
</sup> This observation is consistent with the fact that PPAR-α activators improved endothelial-mediated NO vasodilation.<sup>
<xref ref-type="bibr" rid="bibr19-0960327112454891">19</xref>
</sup> In other words, PPAR-α prevented the development of hypertension and improved myocardial inflammation and collagen deposition in angiotensin-infused rats.<sup>
<xref ref-type="bibr" rid="bibr20-0960327112454891">20</xref>
</sup> Therefore, this suggested that a role exists for PPAR-α as a target for prevention and treatment of myocardial disease. The focus of this study, however, is to actually evaluate the renoprotective effect of fenofibrate, a PPAR-α activated ligand.</p>
<p>The involvement of several vasoconstrictors, including ET1<sup>
<xref ref-type="bibr" rid="bibr28-0960327112454891">28</xref>
</sup> and AII,<sup>
<xref ref-type="bibr" rid="bibr29-0960327112454891">29</xref>
</sup> in haemodynamic changes has been identified. Namely, it has been reported that renal injury induces synthesis of endogenous ET1, which is then able to ensure continuation of its own production, after the initial injury ends. In addition, ET1 has greater vasoconstrictor activity in the renal vasculature than in any other vascular bed and it has direct glomerular and tubular effects.<sup>
<xref ref-type="bibr" rid="bibr30-0960327112454891">30</xref>
</sup> At high concentrations, ET1 induces severe reduction in renal blood flow and glomerular filtration rate (GFR), a fall in the urinary flow rate and a decrease in urinary sodium excretion. ET1 is also able to contract mesangial cells. Renal effects and mesangial cell contraction induced by ET<sup>
<xref ref-type="bibr" rid="bibr31-0960327112454891">31</xref>
</sup> are mediated, at least in part, by platelet-activating factor. AII is also a potent intrarenal vasoconstrictor. It modulates the GFR by directly affecting the tone of both efferent and afferent arterioles, but it also affects mesangial cell function.<sup>
<xref ref-type="bibr" rid="bibr29-0960327112454891">29</xref>
</sup> It was, therefore, in the context of these haemodynamic changes, we set out to evaluate the effect of fenofibrate on AII- and ET1-induced high blood pressure and hence changes in the medullary and CBF.</p>
<p>In this study, after 7 days of fenofibrate administration and thereafter glycerol-induced acute kidney failure, fenofibrate did not blunt high blood pressure in rats when PE, AII and ET1 were administered at different times. As a matter of fact, the MAP was highest in the fenofibrate group when PE, AII and ET1 were administered. This may corroborate the reports of Iglarz et al.<sup>
<xref ref-type="bibr" rid="bibr32-0960327112454891">32</xref>
</sup> that in deoxycorticosterone acetate (DOCA)-salt hypertensive rats, blood pressure increase and endothelial dysfunction were prevented in part by the PPAR-γ activator, rosiglitazone, but not by the PPAR-α activator fenofibrate. Both PPAR activators, however, prevented the enhanced production of reactive oxygen species and the hypertrophic remodeling typically found in blood vessels of DOCA-salt hypertensive rats, consistent with their anti-inflammatory effects.</p>
<p>All the vasodilators used in this study were able to achieve enhanced vasodilation in the presence of fenofibrate. This further corroborates the cardioprotective effect of this agent. With respect to MBF changes, fenofibrate in the presence of PE and AII caused a mixed reaction in that at lower doses, there is increase in pulsation unit and vice-versa. The effect of ET1 and the three vasodilators was similar. Since MBF is a region of low oxygen supply, increasing pulsation may further lead to hypoxia and hence could lead to ischaemia. It is good to note, however, that at higher doses of the vasoconstrictors, the pulsation unit decreased. The effect of fenofibrate on the CBF in the presence of the vasoconstrictors (PE and AII) is similar to that of MBF. In the case of ET1 and the three vasodilators, the pulsation unit experienced increased level and this may to some extent bring about vasodilation and hence renoprotective effect. It should be noted that the cortex constitutes the major portion of the kidney and receives a disproportionately higher percentage (90%) of blood flow compared with the medulla (about 6-10%) or papilla (1–2%). Thus, when a blood-borne toxicant is delivered to the kidney, a high percentage of the material will be delivered to the cortex and will have greater opportunity to influence cortical rather than medullary or papillary functions.<sup>
<xref ref-type="bibr" rid="bibr33-0960327112454891">33</xref>
</sup>
</p>
<p>It was expected that fenofibrate will give a pronounced renoprotective effect; however, the short duration of 7 days as against the usual duration of 25 weeks may have affected this.<sup>
<xref ref-type="bibr" rid="bibr18-0960327112454891">18</xref>
</sup> Again, although PPAR-α is expressed in vascular tissues, it is lacking in renal vasculature.<sup>
<xref ref-type="bibr" rid="bibr34-0960327112454891">34</xref>
</sup> These and others may have accounted for seemingly ineffective haemodynamic changes seen in this study.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure" id="fn1-0960327112454891">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0960327112454891">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yousefipour</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Hercule</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Oyekan</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Newaz</surname>
<given-names>MA</given-names>
</name>
</person-group>. <article-title>Antioxidant U74389G improves glycerol-induced acute renal failure without affecting PPAR-γ gene</article-title>. <source>Ren Fail</source> <year>2007</year>; <volume>29</volume>: <fpage>903</fpage>–<lpage>910</lpage>.</citation>
</ref>
<ref id="bibr2-0960327112454891">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Newaz</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Yousefipour</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Oyekan</surname>
<given-names>AO</given-names>
</name>
</person-group>. <article-title>Role of PPAR-γ on the pathogenesis and vascular changes in glycerol-induced acute renal failure</article-title>. <source>Pharmacol Res</source> <year>2006</year>; <volume>54</volume>: <fpage>234</fpage>–<lpage>240</lpage>.</citation>
</ref>
<ref id="bibr3-0960327112454891">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Devarajan</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Update on mechanisms of ischemic acute kidney injury</article-title>. <source>J Am Soc Nephrol</source> <year>2006</year>; <volume>17</volume>: <fpage>1503</fpage>–<lpage>1520</lpage>.</citation>
</ref>
<ref id="bibr4-0960327112454891">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Goldstein</surname>
<given-names>SL</given-names>
</name>
</person-group>. <article-title>Pediatric acute kidney injury: it’s time for real progress</article-title>. <source>Pediatr Nephrol</source> <year>2006</year>; <volume>21</volume>: <fpage>891</fpage>–<lpage>895</lpage>.</citation>
</ref>
<ref id="bibr5-0960327112454891">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nguyen</surname>
<given-names>MT</given-names>
</name>
<name>
<surname>Devarajan</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Biomarkers for the early detection of acute kidney injury</article-title>. <source>Pediatr Nephrol</source> <year>2008</year>; <volume>23</volume>: <fpage>2151</fpage>–<lpage>2157</lpage>.</citation>
</ref>
<ref id="bibr6-0960327112454891">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Herget-Rosenthal</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Marggraf</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hüsing</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Goring</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pietruck</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Janssen</surname>
<given-names>O</given-names>
</name>
<etal/>
</person-group> <article-title>Early detection of acute renal failure by serum cystatin C</article-title>. <source>Kidney Int</source> <year>2004</year>; <volume>66</volume>: <fpage>1115</fpage>–<lpage>1122</lpage>.</citation>
</ref>
<ref id="bibr7-0960327112454891">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cuzzocrea</surname>
<given-names>S</given-names>
</name>
</person-group>. <article-title>Peroxisome proliferator-activated receptors gamma ligands and ischaemia and reperfusion injury</article-title>. <source>Vasc Pharmacol</source> <year>2005</year>; <volume>41</volume>: <fpage>187</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr8-0960327112454891">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Auboeuf</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Riusset</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Fajas</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Vallier</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Frering</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Riou</surname>
<given-names>JP</given-names>
</name>
</person-group>. <article-title>Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator- activated receptors and liver X receptor-alpha in humans-NO alteration in adipose tissue of obese and NIDDM patients</article-title>. <source>Diabetes</source> <year>1997</year>; <volume>46</volume>: <fpage>1319</fpage>–<lpage>1327</lpage>.</citation>
</ref>
<ref id="bibr9-0960327112454891">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Marx</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bourcier</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sukhova</surname>
<given-names>GK</given-names>
</name>
<name>
<surname>Libby</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Plutzky</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>PPAR-γ activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPAR-γ as a potential mediator in vascular disease</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>1999</year>; <volume>19</volume>: <fpage>546</fpage>–<lpage>551</lpage>.</citation>
</ref>
<ref id="bibr10-0960327112454891">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ijima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Yoshizumi</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ako</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Eto</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hashimoto</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Expression of peroxisome proliferator-activated receptor gamma in rat aortic smooth muscle cells</article-title>. <source>Biochem Biophy Res Comm</source> <year>1998</year>; <volume>247</volume>: <fpage>353</fpage>–<lpage>356</lpage>.</citation>
</ref>
<ref id="bibr11-0960327112454891">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sugawara</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Takeuchi</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Uruno</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Arima</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kudo</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group> <article-title>Transcriptional suppression of type-1 angiotensin II receptor gene expression by peroxisome proliferator activated receptor gamma in vascular smooth muscle cells</article-title>. <source>Endocrinol</source> <year>2001</year>; <volume>142</volume>(<issue>7</issue>): <fpage>3125</fpage>–<lpage>3134</lpage>.</citation>
</ref>
<ref id="bibr12-0960327112454891">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ogihara</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Rakugi</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Ikegami</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Mikami</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Masuo</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives</article-title>. <source>Am J Hypertens</source> <year>1995</year>; <volume>8</volume>: <fpage>316</fpage>–<lpage>320</lpage>.</citation>
</ref>
<ref id="bibr13-0960327112454891">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Imano</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Kanda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nakatani</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Nishida</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Arai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Motomura</surname>
<given-names>M</given-names>
</name>
</person-group>. <article-title>Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy</article-title>. <source>Diabetes Care</source> <year>1998</year>; <volume>21</volume>: <fpage>2135</fpage>–<lpage>2139</lpage>.</citation>
</ref>
<ref id="bibr14-0960327112454891">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Oyekan</surname>
<given-names>AO.</given-names>
</name>
</person-group> <article-title>Peroxisome proliferator-activated receptors (PPARs): the new frontiers in the treatment of cardiovascular diseases</article-title>. <source>Trop J Pharm Res</source> <year>2009</year>; <volume>8</volume>(<issue>2</issue>): <fpage>101</fpage>–<lpage>103</lpage>.</citation>
</ref>
<ref id="bibr15-0960327112454891">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delerive</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Martin-Nizard</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Chinetti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Trottein</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Fruchart</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Najib</surname>
<given-names>J</given-names>
</name>
</person-group>. <article-title>Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway</article-title>. <source>Circ Res</source> <year>1999</year>; <volume>85</volume>: <fpage>394</fpage>–<lpage>402</lpage>.</citation>
</ref>
<ref id="bibr16-0960327112454891">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Staels</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Koenig</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Habib</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Merval</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Lebret</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Torra</surname>
<given-names>IP</given-names>
</name>
</person-group>. <article-title>Activation of human aortic smooth muscle cells is inhibited by PPAR α but not by PPAR γ activators</article-title>. <source>Nature</source> <year>1998</year>; <volume>393</volume>: <fpage>790</fpage>–<lpage>793</lpage>.</citation>
</ref>
<ref id="bibr17-0960327112454891">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Delerive</surname>
<given-names>P</given-names>
</name>
<name>
<surname>De Bosscher</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Besnard</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Vanden Berghe</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Peters</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Gonzalez</surname>
<given-names>FJ.</given-names>
</name>
</person-group> <article-title>Peroxisome proliferator-activated receptor alpha negatively regulates the vascular inflammatory gene response by negative cross-talk with transcription factor NFKB and AP-1</article-title>. <source>J Biol Chem</source> <year>1999</year>; <volume>274</volume>: <fpage>32048</fpage>–<lpage>32054</lpage>.</citation>
</ref>
<ref id="bibr18-0960327112454891">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Banks</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Oyekan</surname>
<given-names>AO</given-names>
</name>
</person-group>. <article-title>Peroxisome proliferator-activated receptor α activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat</article-title>. <source>J Hypertension</source> <year>2008</year>; <volume>26</volume>(<issue>3</issue>):<fpage>468</fpage>–<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr19-0960327112454891">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diep</surname>
<given-names>QN</given-names>
</name>
<name>
<surname>Amiri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Touyz</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Cohn</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Endemann</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Neves</surname>
<given-names>MF</given-names>
</name>
<etal/>
</person-group> <article-title>PPARα activator effects on Ang II-induced vascular oxidative stress and inflammation</article-title>. <source>Hypertens</source> <year>2002</year>; <volume>40</volume>: <fpage>866</fpage>–<lpage>871</lpage>.</citation>
</ref>
<ref id="bibr20-0960327112454891">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Diep</surname>
<given-names>QN</given-names>
</name>
<name>
<surname>Benkirane</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Amiri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Cohn</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Endemann</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Schiffrin</surname>
<given-names>EL</given-names>
</name>
</person-group>. <article-title>PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats</article-title>. <source>J Mol Cell Cardiol</source> <year>2004</year>; <volume>36</volume>: <fpage>295</fpage>–<lpage>304</lpage>.</citation>
</ref>
<ref id="bibr21-0960327112454891">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vera</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Taylor</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bohman</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Flasch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Roman</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Stec</surname>
<given-names>DE</given-names>
</name>
</person-group>. <article-title>Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice</article-title>. <source>Hypertens</source> <year>2005</year>; <volume>45</volume>: <fpage>730</fpage>–<lpage>735</lpage>.</citation>
</ref>
<ref id="bibr22-0960327112454891">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tham</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Martin-McNulty</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y-X</given-names>
</name>
<name>
<surname>Sullivan</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Rutledge</surname>
<given-names>JC</given-names>
</name>
</person-group>. <article-title>PPAR α activation attenuates angiotensin II-induced vascular inflammation, arterial LDL accumulation and endothelial layer permeability in mice</article-title>. <source>J Applied Res</source> <year>2005</year>; <volume>5</volume>: <fpage>1</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr23-0960327112454891">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Baliga</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Ueda</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Walker</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>SV</given-names>
</name>
</person-group>. <article-title>Oxidant mechanism in toxic acute renal failure</article-title>. <source>Drug Metab Rev</source> <year>1999</year>; <volume>31</volume>(<issue>4</issue>): <fpage>971</fpage>–<lpage>997</lpage>.</citation>
</ref>
<ref id="bibr24-0960327112454891">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tabernero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Schoonjans</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Jesel</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Carpusca</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Auwerx</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Andriantsitohaina</surname>
<given-names>R</given-names>
</name>
</person-group>. <article-title>Activation of the peroxisome proliferator activated receptor α protects against myocardial ischemic injury and improves endothelial vasodilatation</article-title>. <source>BMC Pharmacol</source> <year>2002</year>; <volume>2</volume>: <fpage>1</fpage>–<lpage>10</lpage>.</citation>
</ref>
<ref id="bibr25-0960327112454891">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ericsson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Hansten</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nilsson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Grip</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Svane</surname>
<given-names>B</given-names>
</name>
<name>
<surname>de Faire</surname>
<given-names>U</given-names>
</name>
</person-group>. <article-title>Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients</article-title>. <source>Lancet</source> <year>1996</year>; <volume>347</volume>: <fpage>849</fpage>–<lpage>853</lpage>.</citation>
</ref>
<ref id="bibr26-0960327112454891">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Frick</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Syvanne</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nieminen</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Kauma</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Majahalme</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Virtanen</surname>
<given-names>V</given-names>
</name>
<etal/>
</person-group> <article-title>Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol</article-title>. <source>Circulation</source> <year>1997</year>; <volume>96</volume>: <fpage>2137</fpage>–<lpage>2143</lpage>.</citation>
</ref>
<ref id="bibr27-0960327112454891">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dandona</surname>
<given-names>P</given-names>
</name>
</person-group>. <article-title>Endothelium, inflammation, and diabetes</article-title>. <source>Curr Diabetes Report</source> <year>2002</year>; <volume>2</volume>: <fpage>311</fpage>–<lpage>315</lpage>.</citation>
</ref>
<ref id="bibr28-0960327112454891">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lieberthal</surname>
<given-names>W</given-names>
</name>
</person-group>. <article-title>Biology of acute renal failure: therapeutic implications</article-title>. <source>Kidney Int</source> <year>1997</year>; <volume>52</volume>: <fpage>1102</fpage>–<lpage>1115</lpage>.</citation>
</ref>
<ref id="bibr29-0960327112454891">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishikawa</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>RC</given-names>
</name>
</person-group>. <article-title>Angiotensin actions in the kidney: renewed insights into the old hormone</article-title>. <source>Kidney Int</source> <year>1991</year>; <volume>4</volume>: <fpage>583</fpage>–<lpage>596</lpage>.</citation>
</ref>
<ref id="bibr30-0960327112454891">
<label>30</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Katoh</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Chang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Uchida</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Okuda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Kurokawa</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Direct effects of endothelin in the rat kidney</article-title>. <source>Am J Physiol</source> <year>1990</year>; <volume>258</volume>: <fpage>F397</fpage>–<lpage>F402</lpage>.</citation>
</ref>
<ref id="bibr31-0960327112454891">
<label>31</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lopez-Farre</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Gomez-Garre</surname>
<given-names>DN</given-names>
</name>
<name>
<surname>Bernabeu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Montan es</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Millas</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Lopez-Novoa</surname>
<given-names>JM</given-names>
</name>
</person-group>. <article-title>Renal effects and mesangial cell contraction induced by endothelin are mediated by PAF</article-title>. <source>Kidney Int</source> <year>1991</year>; <volume>39</volume>: <fpage>624</fpage>–<lpage>630</lpage>.</citation>
</ref>
<ref id="bibr32-0960327112454891">
<label>32</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Iglarz</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Touyz</surname>
<given-names>RM</given-names>
</name>
<name>
<surname>Amiri</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lavoie</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Diep</surname>
<given-names>QN</given-names>
</name>
<name>
<surname>Schiffrin</surname>
<given-names>EL</given-names>
</name>
</person-group>. <article-title>Effect of peroxisome proliferator-activated receptor-α and -γ activators on vascular remodeling in endothelin-dependent hypertension</article-title>. <source>Arterioscler Thromb Vasc Biol</source> <year>2003</year>; <volume>23</volume>: <fpage>45</fpage>–<lpage>51</lpage>.</citation>
</ref>
<ref id="bibr33-0960327112454891">
<label>33</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname>Scnellmann</surname>
<given-names>RG</given-names>
</name>
</person-group>. <article-title>Toxic responses of the kidney</article-title>. In: <person-group person-group-type="editor">
<name>
<surname>Klaassen</surname>
<given-names>CD</given-names>
</name>
</person-group> (ed.) <source>Casarett and Doull’s toxicology the basic science of poisons</source>. <edition>7th ed</edition>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>The McGraw Hill Medical Companies</publisher-name>, <year>2008</year>, p. <fpage>583</fpage>.</citation>
</ref>
<ref id="bibr34-0960327112454891">
<label>34</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ishizuka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ito</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ogawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kohzuki</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Omata</surname>
<given-names>K</given-names>
</name>
</person-group>. <article-title>Regulation of cytochrome P-450 4A activity by peroxisome proliferator-activated receptors in the rat kidney</article-title>. <source>Hypertens Res</source> <year>2003</year>; <volume>26</volume>: <fpage>929</fpage>–<lpage>936</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>